Lung Cancer Clinical Trials in Houston

Showing 481-500 of 537 trials

Safety Study of Imexon Plus Docetaxel in Lung, Breast or Prostate Cancer Patients

NCT00327288

Protocol AMP-010 is a Phase 1b study of imexon plus docetaxel for patients with previously treated breast cancer, previously treated lung cancer or hormone refractory prostate cancer. Docetaxel is approved by the Food and Drug Administration (FDA) as a second line therapy for these cancers. The imexon is administered on days 1-5 and the docetaxel on day 1 of every 3 week cycle. The objective of the protocol is to determine the highest dose of imexon which can be given with a full dose of docetaxel, and to provide information to enable the design of a future study focused on one or more specific cancer types.

Non-small Cell Lung CancerBreast CancerProstate Cancer

AmpliMed Corporation34 participantsStarted Oct 2005

Houston, Texas, United States

COMPLETEDPhase 1< 1 mile

BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors

NCT00346385

RATIONALE: Monoclonal antibodies, such as BB-10901, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This phase I trial is studying the side effects and best dose of BB-10901 in treating patients with relapsed or refractory solid tumors.

Ovarian CancerMerkel Cell CarcinomaSCLC

ImmunoGen, Inc.97 participantsStarted Mar 2002

San Francisco, California, United States • Las Vegas, Nevada, United States • Columbus, Ohio, United States +6 more locations

Safety Study of Imexon Plus Docetaxel in Lung, Breast or Prostate Cancer Patients

BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors

Lung Cancer Trials in Other Cities

BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLC

PMRR-NO: Pulmonary Metabolic Radiation Response Versus Exhaled Nitric Oxide

National Lung Screening Trial (NLST) Screening

Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)

VNP40101M in Treating Patients With Relapsed or Refractory Locally Advanced or Metastatic Small Cell Lung Cancer

3-AP and Gemcitabine in Treating Patients With Metastatic Non-Small Cell Lung Cancer

Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC

Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer

Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLC

Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors

A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.

S0424 - Carcinogens in Lung Tissue From Smokers (Closed to Entry as of 7/15/07) and Non-Smokers With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

Study of Gemcitabine/Platinum +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

Pemetrexed and Best Supportive Care Versus Placebo and Best Supportive Care in Non-Small Cell Lung Cancer (NSCLC)

Airway Epithelium Gene Expression: AEGIS IDE

A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.

Other Conditions in Houston